Givaudan S&E
This article was originally published in The Rose Sheet
Executive Summary
Fine fragrance revenue grew by double digits for the first nine months due to significant new launches and strong performance of specialty retail and direct-selling channels, Givaudan reports Oct. 9. Consumer Products business experienced high single-digit growth in local currencies with strong win rates achieved in hair care. Fragrance division sales fell 1.7% to $643.9 mil. (CH1=$.76). In local currencies, division sales were up 5.2%. Givaudan's net sales for the period grew 1.1% in Swiss Francs on a reported basis to $1.58 bil. Revenue was down 4.6% on a pro forma basis, assuming the acquisition of Nestle's flavor activities had taken place Jan. 1...
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.